Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV)

NCT05323435 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: Recombinant two-component COVID-19 vaccine (CHO cell)
BIOLOGICAL: COVID-19 Vaccine (Vero Cell), Inactivated

Sponsor

Jiangsu Rec-Biotechnology Co., Ltd.